Intestinal Research

IBD
The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis: Jae Hee Cheon, Kristine Paridaens, Sameer Al Awadhi, Jakob Begun, John R Fullarton, Edouard Louis, Fernando Magro, Juan Ricardo Marquez, Alexander R Moschen, Neeraj Narula, Grazyna Rydzewska, Axel U Dignass, Simon PL Travis; Intest Res. 2023;21(1):161-167. Published online April 18, 2022; DOI: https://doi.org/10.5217/ir.2022.00006
Crossref 1; Full text PubReader ePub PDF Supplementary Material

Gastrointestinal bleeding risk of non-vitamin K antagonist oral anticoagulants versus warfarin in general and after polypectomy: a population-based study with propensity score matching analysis: Jong Yop Pae, Eun Soo Kim, Sung Kook Kim, Min Kyu Jung, Jun Heo, Jang Hoon Lee, Min Ae Park; Intest Res. 2022;20(4):482-494. Published online April 15, 2022; DOI: https://doi.org/10.5217/ir.2021.00161
Crossref 3; Full text PubReader ePub PDF Supplementary Material

IBD
Long-term clinical and real-world experience with Crohn’s disease treated with anti-tumor necrosis factor-α antibodies: Haruka Otake, Satohiro Matsumoto, Hirosato Mashima; Intest Res. 2022;20(4):464-474. Published online March 31, 2022; DOI: https://doi.org/10.5217/ir.2021.00139
Web of Science 4 Crossref 4; Full text PubReader ePub PDF

Intestinal ultrasonography and fecal calprotectin for monitoring inflammation of ileal Crohn’s disease: two complementary tests: José María Paredes, Tomás Ripollés, Ángela Algarra, Rafael Diaz, Nadia Moreno, Patricia Latorre, María Jesús Martínez, Pilar Llopis, Antonio López, Eduardo Moreno-Osset; Intest Res. 2022;20(3):361-369. Published online March 15, 2022; DOI: https://doi.org/10.5217/ir.2021.00126
Web of Science 3 Crossref 5; Full text PubReader ePub PDF

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial: Toshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, Fumihito Hirai, Kenji Watanabe, Katsuyoshi Matsuoka, Masayuki Saruta, Taku Kobayashi, Brian G Feagan, Chantal Tasset, Robin Besuyen, Chohee Yun, Gerald Crans, Jie Zhang, Akira Kondo, Mamoru Watanabe; Intest Res. 2023;21(1):110-125. Published online March 11, 2022; DOI: https://doi.org/10.5217/ir.2021.00143
Web of Science 10 Crossref 9; Full text PubReader ePub PDF Supplementary Material

Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis: Katsuyoshi Matsuoka, Kanae Togo, Noritoshi Yoshii, Masato Hoshi, Shoko Arai; Intest Res. 2023;21(1):88-99. Published online March 11, 2022; DOI: https://doi.org/10.5217/ir.2021.00154
Web of Science 3 Crossref 3; Full text PubReader ePub PDF Supplementary Material

Physician education can minimize inappropriate steroid use in patients with inflammatory bowel disease: the ACTION study: Yehyun Park, Chang Hwan Choi, Hyun Soo Kim, Hee Seok Moon, Do Hyun Kim, Jin Ju Kim, Dennis Teng, Dong Il Park; Intest Res. 2022;20(4):452-463. Published online March 11, 2022; DOI: https://doi.org/10.5217/ir.2021.00125
Web of Science 2 Crossref 2; Full text PubReader ePub PDF Supplementary Material

Update on SARS-CoV-2 vaccination of patients with inflammatory bowel disease: what clinicians need to know: Yoo Jin Lee, Seong-Eun Kim, Yong Eun Park, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Seung-Jae Myung, Clinical Practice Guideline Committee of the Korean Association for the Study of Intestinal Diseases; Intest Res. 2022;20(3):386-388. Published online March 11, 2022; DOI: https://doi.org/10.5217/ir.2020.00172; Full text PubReader ePub PDF

Colonic oncostatin M expression evaluated by immunohistochemistry and infliximab therapy outcome in corticosteroid-refractory acute severe ulcerative colitis: Jim O’Connell, Jayne Doherty, Amy Buckley, David Cormican, Cara Dunne, Karen Hartery, John Larkin, Finbar MacCarthy, Paul McCormick, Susan McKiernan, Brian Mehigan, Cian Muldoon, Ciara Ryan, Jacintha O’Sullivan, David Kevans; Intest Res. 2022;20(3):381-385. Published online March 11, 2022; DOI: https://doi.org/10.5217/ir.2021.00073
Web of Science 1 Crossref 1; Full text PubReader ePub PDF Supplementary Material

Efficacy of hepatitis B vaccination in patients with ulcerative colitis: a prospective cohort study: Anurag Mishra, Amarender Singh Puri, Sanjeev Sachdeva, Ashok Dalal; Intest Res. 2022;20(4):445-451. Published online February 8, 2022; DOI: https://doi.org/10.5217/ir.2021.00106
Web of Science 1 Crossref 2; Full text PubReader ePub PDF

Endoscopy for assessment of mucosal healing in ulcerative colitis: time bound or response guided?: Ajit Sood, Ramit Mahajan, Arshdeep Singh, Vandana Midha, Varun Mehta; Intest Res. 2022;20(3):297-302. Published online February 8, 2022; DOI: https://doi.org/10.5217/ir.2021.00099
Web of Science 4 Crossref 4; Full text PubReader ePub PDF

Miscellaneous
Endoscopic balloon dilations for strictures of rectum, ileocecal valve and duodenum in a patient with X-linked inhibitor of apoptosis deficiency: a case report: Shinsuke Otagiri, Takehiko Katsurada, Kensuke Sakurai, Junichi Sugita, Naoya Sakamoto; Intest Res. 2022;20(2):274-277. Published online February 8, 2022; DOI: https://doi.org/10.5217/ir.2021.00029; Full text PubReader ePub PDF

IBD
Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis: Nagesh Kamat, Sudheer K Vuyyuru, Saurabh Kedia, Pabitra Sahu, Bhaskar Kante, Peeyush Kumar, Mukesh Kumar Ranjan, Mukesh Kumar Singh, Sambuddha Kumar, Vikas Sachdev, Govind Makharia, Vineet Ahuja; Intest Res. 2022;20(2):269-273. Published online February 8, 2022; DOI: https://doi.org/10.5217/ir.2021.00064
Web of Science 4 Crossref 5; Full text PubReader ePub PDF Supplementary Material

Fecal microbiota transplantation for induction of remission, maintenance and rescue in patients with corticosteroid-dependent ulcerative colitis: a long-term follow-up real-world cohort study: Avnish Kumar Seth, Priti Jain; Intest Res. 2022;20(2):251-259. Published online February 8, 2022; DOI: https://doi.org/10.5217/ir.2021.00069
Web of Science 3 Crossref 5; Full text PubReader ePub PDF

Vedolizumab for perianal fistulizing Crohn’s disease: systematic review and meta-analysis: Fares Ayoub, Matthew Odenwald, Dejan Micic, Sushila R. Dalal, Joel Pekow, Russell D. Cohen, David T. Rubin, Atsushi Sakuraba; Intest Res. 2022;20(2):240-250. Published online February 8, 2022; DOI: https://doi.org/10.5217/ir.2021.00091
Web of Science 8 Crossref 9; Full text PubReader ePub PDF Supplementary Material

Search